ArticleCancer biomarkers : section A of Disease markers2020
Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
Article in Cancer biomarkers : section A of Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Emerging technologies for monitoring breast cancer response to neoadjuvant chemotherapy: a systematic scoping review.Breast (Edinburgh, Scotland) · 2026Review
- Long Non-Coding RNAs in HER2-Positive Breast Cancer: From Resistance Mechanisms to Translational Potential.Oncology research · 2026Review
- Review
- Expanding the horizon of EV-RNAs: LncRNAs in EVs as biomarkers for disease pathways.Extracellular vesicle · 2023Article
- The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer.International journal of molecular sciences · 2023Review
- Application value of circulating LncRNA in diagnosis, treatment, and prognosis of breast cancer.Functional & integrative genomics · 2023Review
- New progress in the role of microRNAs in the diagnosis and prognosis of triple negative breast cancer.Frontiers in molecular biosciences · 2023Review
- Effect of Cytotoxic Therapy on ALU Expression is Modulated by Hormonal Status in Patients with Breast CancerBalkan medical journal · 2022Article
- lncRNA H19 promotes glioblastoma multiforme development by activating autophagy by sponging miR-491-5p.Bioengineered · 2022Article
- Review
- The long non-coding RNA landscape in triple-negative breast cancer.Cell proliferation · 2021Review
- LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1.Bioengineered · 2020Article
- Review
- An updated review of the H19 lncRNA in human cancer: molecular mechanism and diagnostic and therapeutic importance.Molecular biology reports · 2020Review
- Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance.Molecular cancer · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNovel biomarkers are needed to predict the effectiveness of the treatment of presurgical neoadjuvant chemotherapy (NAC) in breast cancer (BC).
objectiveThis is an exploratory study to assess the impact of 3 cancer-related long non-coding RNAs (lncRNAs) (H19, MALAT1 and GA5) in blood plasma of patients with BC in predicting the response to NAC.
methodsThe plasma levels of RNAs were relatively measured by quantitative PCR at baseline, and at the end of the fourth cycle of NAC in patients with locally advanced BC.
resultsOnly H19 was associated with patients' characteristics, and with the response to NAC. Higher plasma expression of H19 was associated with younger age at diagnosis, triple negative tumors, and Ki-67 index. Patients with a pathological complete response (20%) had lower pre-therapeutic levels of H19 compared with the non-complete responders (relative levels 0.1 vs 0.2, respectively, P: 0.04). In addition, the patients with higher degree of downstaging of initial tumors had lower baseline levels of H19 among non-complete responders.
conclusionOur study reveals that H19, but not MALAT1 and GAS5, may be a useful marker of response to NAC in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.